A FAUX TUMOUR OF THE CANCER
Main Article Content
Keywords
Parathyroidism, Browns tumour, Parathyroid hormone
Abstract
Browns tumour is a rare tumour like lesion of the bone, which is considered as an end stage lesion of abnormal bone metabolism caused by persistently high parathyroid hormone levels. These are highly vascular osteopathic lesions. In hyperparathyroidism patients instead of neoplasticism it depicts a reparable cellular process. Either these tumours can be aggressive or destructive. It can be seen in any part of the skeleton. Sometimes it can be seen multiple bones and misdiagnosed as metastatic tumour
References
1. Sun B, Guo B, Wu B, et al. Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016. Osteoporos Int
2018; 29:635.
2. Lazaretti-Castro M. The diagnosis of primary hyperparathyroidism in developing countries remains in the past century: still with bones, stone and groans. Arch Endocrinol Metab 2020; 64:101.
3. Yadav SK, Johri G, Bichoo RA, et al. Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Arch Endocrinol Metab 2020; 64:105.
4. Arya AK, Kumari P, Bhadada SK, et al. Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. J Bone Miner Metab 2021; 39:253.
5. Mithal A, Kaur P, Singh VP, et al. ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM EXISTS IN NORTH INDIA: RETROSPECTIVE DATA FROM 2 TERTIARY CARE CENTERS. Endor Pract 2015; 21:581.
6. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism.] Clin Endocrinol Metab 1996; 81:2036.
7. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3580.
8. Siperstein AE, Shen W, Chan AK, et al. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg 1992; 127:1157
2. Lazaretti-Castro M. The diagnosis of primary hyperparathyroidism in developing countries remains in the past century: still with bones, stone and groans. Arch Endocrinol Metab 2020; 64:101.
3. Yadav SK, Johri G, Bichoo RA, et al. Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Arch Endocrinol Metab 2020; 64:105.
4. Arya AK, Kumari P, Bhadada SK, et al. Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. J Bone Miner Metab 2021; 39:253.
5. Mithal A, Kaur P, Singh VP, et al. ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM EXISTS IN NORTH INDIA: RETROSPECTIVE DATA FROM 2 TERTIARY CARE CENTERS. Endor Pract 2015; 21:581.
6. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism.] Clin Endocrinol Metab 1996; 81:2036.
7. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3580.
8. Siperstein AE, Shen W, Chan AK, et al. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg 1992; 127:1157